<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201103133485N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2011-06-14</date_registration>
      <primary_sponsor>Vice Chancellor for research, Guilan University of Medical Sciences</primary_sponsor>
      <public_title>To study the effect of intravenous low dose ketamin on the severity of pain and the need for analgesics in patients operated with cesarean section with spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Scientific title:To study the effect of intravenous low dose ketamin on the severity of pain and the need for analgesics in patients operated with cesarean section with spinal anesthesia in Al-Zahra hospital  during2011</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/3596</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Pregnancy, childbirth and the puerperium.</hc_freetext>
      <i_freetext>Intervention 1: 2cc Normal saline in control group as placebo. Intervention 2: 0.2 mg/kg intra venous ketamin+ 2 ‍cc normal saline in intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Forozan Milani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Reproduction Health Research Center, Al-Zahra hospital, Namjo street</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 13 1322 5624</telephone>
        <email>forozanmilani@yahoo.com</email>
        <affiliation>Guilan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Forozan Milani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Reproductive health Research Center, Al-Zahra Hospital, Namjoo Avenue</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 32 25624</telephone>
        <email>forozanmilani@yahoo.com</email>
        <affiliation>Guilan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria's: 1) Pregnant women with single pregnancy, term, candidate for elective cesarean, 2) Cesarean with pfanenstail incision, 3) No history of drug abuse, 4) Absence of chronic disease such as diabetes mellitus, hypertension, preeclampsia, infection, 5) Surgery performed with the spinal anesthesia by using epinephrined lidocaine, 6) No history of surgery, 7) Having a level of intelligence for optimum cooperation, 8)ASA1 class, 9) Patient with pain score more than 5.&#13;
Exclusion criteria's: 1) Bleeding after surgery, 2) Definite sensitivity to ketamin, 3) Mental and psychological problems., 4) Contraindication for spinal anesthesia, 5) Past history of hypertension, 6) Increased intracranial pressure.&#13;
7) Past history of seizure, 8) Past history of  hallucination after ketamin, 9) Class ASA &gt; 1</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anaesthesia during labour and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>2cc Normal saline in control group as placebo</i_keyword>
      <i_keyword>0.2 mg/kg intra venous ketamin+ 2 ‍cc normal saline in intervention group</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determining the effect of low dose intra venous ketamin compared with intra venous Normal saline on the severity of pain and the need for analgesic in cesarean patients with spinal anesthesia. Timepoint: 0,30,60,90,120,150,180 minutes and 6,12,18,24 hours after cesarean. Method of measurement: Pain score in visual scale in 0,30,60,90,120,150,180 minutes and 6,12,18,24 hours after cesarean section, the time of the first request analgesic, total received analgesics.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparing the pain score after surgery in patients with intra venous ketamin versus intra venous Normal saline group. Timepoint: 0,30,60,90,120,150,180 minutes and 6,12,18,24 hours after cesarean section. Method of measurement: Pain visual scale.</sec_outcome>
      <sec_outcome>Determining the relative frequency of hallucination in group with intravenous ketamin. Timepoint: First 24 hours after cesarean section. Method of measurement: According to patient's answers.</sec_outcome>
      <sec_outcome>Determining the time point from ending cesarean section to the first dose of analgesic in patients with intra venous ketamin. Timepoint: The first 24 hours after cesarean section. Method of measurement: Time of the first request for analgesic (suppository diclofenac).</sec_outcome>
      <sec_outcome>Determining newborn apgar score in group using intra venous Normal saline. Timepoint: First and fifth minutes after birth. Method of measurement: Including 5 sections: heart rate, breathing, effort muscular tone, reflexes, color.</sec_outcome>
      <sec_outcome>Comparing the newborn mean apgar in using Normal saline  versus intra venous ketamin. Timepoint: First and fifth minutes after birth. Method of measurement: Including 5 sections: heart rate, breathing, effort muscular tone, reflexes, color.</sec_outcome>
      <sec_outcome>Determining the relative frequency of complications (vomiting, nausea, headache) in patients using intra venous ketamin. Timepoint: First 24 hours after cesarean section. Method of measurement: Nausea and headache: according to patient’s words. Vomiting : observation expulsion of content with pressure upper gastro intestinal.</sec_outcome>
      <sec_outcome>Determining the relative frequency of complications (vomiting. nausea, headache) in patient by using Normal saline. Timepoint: First 24 hours after cesarean section. Method of measurement: Nausea and headache: according to patient’s words. Vomiting: Observation expulsion of content with pressure upper gastro intestinal.</sec_outcome>
      <sec_outcome>Comparing the relative frequency in group with intra venous ketmin versus intravenous Normal saline. Timepoint: First 24 hours after cesarean section. Method of measurement: Nausea and headache: according to patient’s words. Vomiting: observation expulsion of content with pressure upper gastro intestinal.</sec_outcome>
      <sec_outcome>Determining newborn apgar score in group using intra venous ketamin. Timepoint: First and fifth minutes after birth. Method of measurement: Including 5 sections: heart rate, breathing, effort muscular tone, reflexes, color.</sec_outcome>
      <sec_outcome>Determining the time point from ending cesarean section the first dose of analgesic in patients in Normal saline group. Timepoint: The first 24 hours after cesarean section. Method of measurement: Time of the first request for analgesic (diclofenac suppository).</sec_outcome>
      <sec_outcome>Comparing the time point from ending cesarean section to the first analgesic in group with intra venous ketamin versus intra venous Normal Saline group. Timepoint: The first 24 hours after cesarean section. Method of measurement: Time of the first request for analgesic (Diclofenac suppository).</sec_outcome>
      <sec_outcome>Determining the pain score after surgery in patients with cesarean with spinal anesthesia using intra venous normal saline. Timepoint: ,30,60,90,120,150,180 minutes and 6,12,18,24 hours after cesarean section. Method of measurement: Pain visual scale.</sec_outcome>
      <sec_outcome>Comparing the mean dose of pethidine in group with intra venous ketamin versus intra venous Normal saline group. Timepoint: First 24 hours after cesarean section. Method of measurement: Dose of used pethidine. (mg/kg).</sec_outcome>
      <sec_outcome>Determining the pain score after surgery in patients with cesarean with spinal anesthesia using intra venous ketamin. Timepoint: 0,30,60,90,120,150,180 minutes and 6,12,18,24 hours after cesarean section. Method of measurement: Pain visual scale.</sec_outcome>
      <sec_outcome>Determining the mean dose of used pethidin in group of intra venous ketamin. Timepoint: First 24 hours after cesarean. Method of measurement: Dose of used pethidin. (mg/kg).</sec_outcome>
      <sec_outcome>Determining the mean dose of used pethidin in group of using Normal saline. Timepoint: First 24 hours after cesarean section. Method of measurement: Dose of used pethidin. (mg/kg).</sec_outcome>
      <sec_outcome>Comparing the mean dose of sodium diclofenac suppository in patient using intra venous ketamin versus Normal saline. Timepoint: First 24 hours after cesarean section. Method of measurement: Score more than 5 in pain visual scale.</sec_outcome>
      <sec_outcome>Determining mean dose used sodium diclofenac suppository in the group by using Normal saline. Timepoint: First 24 hours after cesarean. Method of measurement: Number of used suppositories.</sec_outcome>
      <sec_outcome>Determining of the mean dose of sodium diclofenac suppository in group using intra venous ketamin. Timepoint: The first 24 hours after cesarean. Method of measurement: Number of used suppository.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for research, Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-03-14</approval_date>
        <contact_name>Ethic committee Guilan University of Medical Sciences</contact_name>
        <contact_address>Melat st, Namjoo Ave Rasht  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
